Journal
ACS CHEMICAL NEUROSCIENCE
Volume 10, Issue 1, Pages 482-496Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.8b00357
Keywords
Alzheimer's disease; multifunctional agents; AChE inhibitors; MAO-B inhibitors; metal chelating agents
Funding
- National Natural Science Foundation of China [21702061, 21672064, 81522045]
- Shanghai Sailing Program [17YF1403600]
- National Key R&D Program of China [2017YF130202600]
- Shu Guang project - Shanghai Municipal Education Commission
- Shanghai Education Development Foundation [14SG28]
- Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12040207]
- Fundamental Research Funds for the Central Universities
Ask authors/readers for more resources
Multifunctional agents aiming at cholinesterases (ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer's disease (AD). Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivatives (1-4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD. Most of these derivatives inhibited ChEs and MAOs with IC50 values in the micro- or nanomolar ranges. Compound 1c displayed the dual functional profile of targeting the AChE (IC50 = 0.032 +/- 0.007 mu M) and MAO-B (IC50 = 2.117 +/- 0.061 mu M), along with the improved blood-brain barrier (BBB) permeability, antioxidant ability, and good copper chelating property in vitro. Animal studies showed that compound 1c center dot HCl could inhibit the cerebral AChE/MAO-B activities and alleviate scopolamine induced cognitive impairment in mice. Combined with good oral bioavailability (F = 45.55%), these findings demonstrated that compound 1c may be a potent brain permeable multifunctional candidate for the treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available